Respir Investig . Empirical antibiotic usage and bacterial superinfections in patients with COVID-19 in Japan: A nationwide survey by the Japanese Respiratory Society

[tetano]

Respir Investig


. 2021 Oct 7;S2212-5345(21)00159-3.
doi: 10.1016/j.resinv.2021.09.004. Online ahead of print.
Empirical antibiotic usage and bacterial superinfections in patients with COVID-19 in Japan: A nationwide survey by the Japanese Respiratory Society


Takahiro Takazono ¹ , Hiroshi Mukae ² , Koichi Izumikawa ³ , Hiroshi Kakeya ⁴ , Tadashi Ishida ⁵ , Naoki Hasegawa ⁶ , Akihito Yokoyama ⁷



Affiliations

• PMID: 34656520
• DOI: 10.1016/j.resinv.2021.09.004

Abstract

An internet questionnaire survey for investigating empirical antibiotic usage and bacterial superinfections in patients with coronavirus disease-2019 (COVID-19) in Japan was conducted among the chief physicians of respiratory disease departments of 715 Japanese Respiratory Society-certified hospitals using Google Forms between January 28, 2021 and February 28, 2021. Responses to the questionnaire survey were obtained from 198 of 715 hospitals (27.6%). The survey revealed that the complication incidences of community-acquired pneumonia; hospital-acquired pneumonia, including ventilator-associated pneumonia; and sepsis were 2.86, 5.59, and 0.99%, respectively, among patients with moderate/severe and critical COVID-19. Bacterial co-infection and secondary infection rarely affected patients with COVID-19 in Japan, and the isolated pathogens were not specific to these patients. Moreover, the anti-inflammatory effects of macrolides for COVID-19 were not observed in several studies. These results might be useful in clinical practice for COVID-19.

Keywords: Antibiotic stewardship; COVID-19; Community-acquired pneumonia; Hospital-acquired pneumonia; Sepsis.